Evidence map›Paper›PMID 35706452›Full record

ArticleFrontiers in genetics2022

The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD).

Shiyong Xin, Xianchao Sun, Liang Jin, Weiyi Li, Xiang Liu, Liqing Zhou, Lin Ye

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. CSF2 polarized neutrophils and invaded renal cancer cellsOpen medicine (Warsaw, Poland) · 2025
    Article
  3. Article
  4. Article
  5. Comparative efficacy of radical prostatectomy and radiotherapy in the treatment of high-risk prostate cancer.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Shiyong XinDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Xianchao SunDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Liang JinDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Weiyi LiDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Xiang LiuDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Liqing ZhouDepartment of Rheumatology and Immunology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Lin YeDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai East Hospital · CNFirst Affiliated Hospital of Henan University of Science and Technology · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is growing evidence that phagocytosis regulatory factors (PRFs) play important roles in tumor progression, and therefore, identifying and characterizing these factors is crucial for understanding the mechanisms of cellular phagocytosis in tumorigenesis. Our research aimed to comprehensively characterize PRFs in prostate adenocarcinoma (PRAD) and to screen and determine important PRFs in PRAD which may help to inform tumor prognostic and therapeutic signatures based on these key PRFs. Here, we first systematically described the expression of PRFs in PRAD and evaluated their expression patterns and their prognostic value. We then analyzed prognostic phagocytic factors by Cox and Lasso analysis and constructed a phagocytic factor-mediated risk score. We then divided the samples into two groups with significant differences in overall survival (OS) based on the risk score. Then, we performed correlation analysis between the risk score and clinical features, immune infiltration levels, immune characteristics, immune checkpoint expression, IC50 of several classical sensitive drugs, and immunotherapy efficacy. Finally, the Human Protein Atlas (HPA) database was used to determine the protein expression of 18 PRF characteristic genes. The aforementioned results confirmed that multilayer alterations of PRFs were associated with the prognosis of patients with PRAD and the degree of macrophage infiltration. These findings may provide us with potential new therapies for PRAD.

Indexed as

immune infiltrationphagocytic factorPRADprostate cancersurvival analysis

Identifiers

PMID35706452
PMCPMC9190300
OpenAlexW4281936710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.